Key Takeaway: The article discusses the Phase 2 MAGNIFY data for Zervimesine, which reportedly slows the growth of geographic atrophy lesions. However, the content primarily directs readers to a third-party website without providing detailed insights or analysis on the study results or implications.
Price reaction · baseline $0.3011 (2025-05-09 close) · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+8.6%
day 1
+6.7%
day 3
+4.6%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.